{"product_id":"lucifine-finerenone","title":"LUCIFINE (Finerenone)","description":"\u003ch2\u003eAbout Finerenone \u003c\/h2\u003e\u003cp\u003eFinerenone is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type\u003cspan class=\"nowrap\"\u003e \u003c\/span\u003e2 diabetes.\u003csup id=\"cite_ref-FDA_Kerendia_8-1\" class=\"reference\"\u003e\u003c\/sup\u003e Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA).\u003c\/p\u003e\u003ch3\u003eChronic Kidney Disease\u003c\/h3\u003e\u003cp\u003eIndicated to reduce risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes\u003c\/p\u003e\u003ch4\u003eStarting dose\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eDetermine starting dose by eGFR (mL\/min\/1.73m\u003csup\u003e2\u003c\/sup\u003e)\u003c\/li\u003e\n\u003cli\u003eeGFR ≥60: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eeGFR 25-60: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eeGFR \u0026lt;25: Not recommended\u003c\/li\u003e\n\u003cli\u003eIncrease dosage after 4 weeks to the target dose of 20 mg qDay based on eGFR and serum potassium thresholds\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose adjustment\u003c\/h4\u003e\u003cp\u003eDose adjustment based on current serum potassium concentration (mEq\/L) and current dose\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eCurrently taking 10 mg qDay\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e≤4.8 mEq\/L: Increase dose to 20 mg qDay; if eGFR has decreased by more than 30% compared to previous measurement, maintain 10 mg dose\u003c\/li\u003e\n\u003cli\u003e\u0026gt;4.8-5.5 mEq\/L: Maintain 10 mg\/day\u003c\/li\u003e\n\u003cli\u003e\u0026gt;5.5 mEq\/L: Withhold dose; consider restarting at 10 mg qDay when potassium ≤5 mEq\/L\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eCurrently taking 20 mg qDay\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e≤4.8 mEq\/L: Maintain 20 mg qDay\u003c\/li\u003e\n\u003cli\u003e\u0026gt;4.8-5.5 mEq\/L: Maintain 20 mg\/day\u003c\/li\u003e\n\u003cli\u003e\u0026gt;5.5 mEq\/L: Withhold dose; restart at 10 mg qDay when potassium ≤5 mEq\/L\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eeGFR 15 to \u0026lt;90 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e: No clinically relevant differences in AUC or peak plasma concentration\u003c\/li\u003e\n\u003cli\u003eInitial dose and adjustments are based on eGFR and serum potassium levels\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh A or B): No dosage adjustment recommended\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797956096043,"sku":"RL20250101s50","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1367.jpg?v=1787022250","url":"https:\/\/xomeds.com\/products\/lucifine-finerenone","provider":"XOMEDS","version":"1.0","type":"link"}